As shown in Supplementary Fig. 4, patients with CXCR5+CD8+T-high tumor have superior OS than patients with CXCR5+CD8+T-low tumor in the MSI-low/MSS, MSI-high, and EBV-negative subgroups (P < 0.001, P = 0.006, and P = 0.034, respectively; Supplementary Fig. 4a, b). This evidence concerns the gene CXCR5 and neoplasm.